查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853783

中枢神经系统治疗市场依适应症、作用机转、给药途径、最终用户及通路划分－2025-2032年全球预测

Central Nervous System Therapeutics Market by Indication, Mechanism Of Action, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，中枢神经系统治疗市场将成长至 2,550.4 亿美元，复合年增长率为 7.48%。

关键市场统计数据
基准年2024年 1431.1亿美元
预计年份：2025年 1532.5亿美元
预测年份 2032 2550.4亿美元
复合年增长率 (%) 7.48%

针对不断发展的中枢神经系统治疗生态系统，制定简洁的策略方向，整合科学进步、监管动态与医疗服务转型。

中枢神经系统治疗生态系统正处于关键的十字路口，科学突破、监管创新和医疗服务模式的转变正在汇聚，重塑药物研发和商业化进程。分子生物学、载体工程和抗体设计的进步正在加速从症状治疗转变为缓解疾病疗法的转变。同时，医疗系统正在调整治疗路径，更加重视慢性病管理和居家医疗，这为针对不同给药途径和环境优化的治疗药物创造了机会和需求。

在此背景下，相关人员必须应对科学机会与营运挑战之间错综复杂的相互作用。生技药品和基因治疗方法潜力巨大，但也增加了生产的复杂性和供应链的敏感性。小分子和胜肽类药物因其广泛的可及性以及口服和经皮给药而仍然重要。支付者和医疗服务提供者越来越需要可靠的真实世界证据和基于价值的合约框架，以控制高成本治疗创新带来的预算影响。因此，整合研发重点、生产能力、上市计画和通路策略的策略观点对于在维持商业性可行性的同时改善病患疗效至关重要。

本执行摘要总结了关键的变革驱动因素，检验了影响该行业的政策和贸易压力，解读了市场细分和区域动态，并为致力于将科学前景转化为永续的临床和商业性影响的领导者提供了切实可行的建议。分析强调了多学科合作、对循证医学的投入以及积极主动的供应链管理对于中枢神经系统治疗领域计画成功的重要性。

精准治疗方式的创新和监管政策的调整将如何改变中枢神经系统药物的研发、商业化和递送方式？

中枢神经系统治疗领域正经历变革性的转变，这主要得益于技术、监管和医疗服务模式的融合。基因疗法和单株抗体等精准治疗方法正从概念验证阶段走向计画阶段，这需要专门的生产製造、目标患者的精准识别以及新型的医保报销机制。同时，血脑障壁调控和递送平台技术的进步正在拓展可行的分子干预手段，使能够以更高的特异性直接作用于中枢神经系统靶点，并可能减少全身性副作用。

医疗服务模式的创新正在重塑医疗服务的提供方式和地点。虽然医院在急诊和复杂疾病的治疗中仍然发挥着核心作用，但诊所和居家医疗在慢性病和復健期护理管理方面承担着越来越重要的责任。这种转变凸显了给药途径设计的重要性－注射与口服或经皮给药相比，需要不同的物流规划。

同时，法律规范也在进行调整，以适应高影响力疗法的快速审批途径，并整合新的终点指标和替代标记。监管机构优先考虑强有力的安全监测和真实世界证据的生成，这正在影响临床开发方案和核准后的承诺。同时，相关人员正在加快学术中心、受託製造厂商以及专科药房之间的合作，以应对复杂性并缩短患者用药时间。这种变革性的转变有利于那些能够将科学敏捷性与营运严谨性以及在研发、监管、生产和商业化等各个环节的相关人员合作相结合的机构。

评估不断变化的贸易压力和关税主导的供应链应对措施，这些措施正在重塑中枢神经系统药物的采购、生产和获取策略。

包括关税措施在内的政策环境对中枢神经系统治疗药物和器械的原料采购、组件供应以及成本结构有具体的影响。关税变化可能会加剧依赖特殊原料、单一来源生技药品成分和复杂生产投入的产业的现有脆弱性。随着进口活性药物原料药、病毒载体和关键生产设备的关税提高，製造商将面临更高的投入成本，进而对生产计划、库存策略以及与支付方和医疗服务提供者的价格谈判产生连锁反应。

2025年关税的累积影响可能会凸显那些为了成本效益而牺牲韧性，优化全球供应链的企业所面临的策略权衡。为此，许多企业正在评估近岸外包或在地化策略，以降低贸易政策波动带来的风险。此外，企业也在重新评估其供应商组合，并寻找替代供应商，以实现关键试剂和组件来源的多元化。虽然这些调整可以缓解未来的关税衝击，但需要严格的品质监控和验证，以确保治疗方法的完整性。

对于医院和诊所而言，关税导致的采购成本增加可能会使预算更加紧张，迫使它们优先考虑具有明确价值主张的治疗方法，并实施更严格的处方管理。家庭护理服务提供者和分销管道受到的影响可能因对进口设备和专用包装的依赖程度而有所不同。整体而言，关税变化的累积效应将凸显供应链透明度、库存优化以及贯穿采购、居家照护和销售等各个环节的综合成本削减策略的重要性。

主导的策略要务，旨在调整管理设定和通路，以适应不同的模式，从而优化发展路径并实现预期成果。

细分领域的细微差别决定了治疗开发和商业化活动中的机会窗口和营运要求。基于适应症的研究涵阿兹海默症、注意力不足过动症、忧郁症、癫痫、多发性硬化症、神经病变疼痛、帕金森氏症和中风，每种疾病都有其独特的患者识别、终点选择的复杂性以及与支付方谈判的挑战。阿兹海默症和帕金森氏症计画着重于缓解疾病和生物标记整合，注意力不足过动症和忧郁症则优先考虑快速改善症状和提高依从性，而癫痫和中风干预措施通常与急性期护理和康復路径交织在一起。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 基因治疗方法在治疗难治性神经系统疾病的应用日益广泛
  • 将数位生物标记整合到临床试验中，加速中枢神经系统药物研发
  • 扩大阿兹海默症中淀粉样蛋白和Tau的单株抗体疗法
  • 人们越来越关注药物基因组学筛检在个人化忧郁症和焦虑症管理的应用。
  • 针对帕金森氏症神经发炎路径的小分子抑制剂数量不断增加
  • 脊髓内和鼻内给药平台的进展有助于克服血脑障壁
  • 生物技术新兴企业与大型製药公司建立策略伙伴关係，以实现中枢神经系统产品线多元化策略

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依适应症分類的中枢神经系统药物市场

  • 阿兹海默症
  • 注意力不足过动症
  • 忧郁症
  • 癫痫
  • 多发性硬化症
  • 神经病变疼痛
  • 帕金森氏症
  • 中风

9. 依作用机转分類的中枢神经系统治疗药物市场

  • 基因治疗
  • 单株抗体
  • 胜肽
  • 小分子

第十章：依给药途径分類的中枢神经系统药物市场

  • 注射
  • 口服
  • 经皮

第十一章：按最终用户分類的中枢神经系统药物市场

  • 诊所
  • 居家照护
  • 医院

12. 中枢神经系统药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药局

13. 各地区中枢神经系统药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 中枢神经系统药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国中枢神经系统药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Johnson & Johnson
    • Roche Holding AG
    • Novartis AG
    • Pfizer Inc.
    • Biogen Inc.
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd.
    • Otsuka Pharmaceutical Co., Ltd.
Product Code: MRR-02026C4C9A19

The Central Nervous System Therapeutics Market is projected to grow by USD 255.04 billion at a CAGR of 7.48% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 143.11 billion
Estimated Year [2025] USD 153.25 billion
Forecast Year [2032] USD 255.04 billion
CAGR (%) 7.48%

A concise strategic orientation to the evolving central nervous system therapeutics ecosystem that integrates scientific advances regulatory dynamics and care delivery transformations

The central nervous system therapeutics ecosystem is at a pivotal juncture where scientific breakthroughs, regulatory innovation, and shifting care delivery models converge to reshape development and commercialization pathways. Advances in molecular biology, vector engineering, and antibody design have accelerated the transition from symptomatic therapies toward disease-modifying approaches, while an expanding set of digital and diagnostic tools is improving patient identification and outcome measurement. At the same time, health systems are recalibrating care pathways to emphasize chronic disease management and home-based care, creating opportunities and demands for therapies optimized for different administration routes and settings.

Against this backdrop, stakeholders must navigate a complex interplay of scientific opportunity and operational challenge. Biologics and gene-based modalities bring high potential but also elevated manufacturing complexity and supply chain sensitivity. Small molecules and peptides remain important for broad accessibility and oral and transdermal delivery. Payers and providers are increasingly seeking robust real-world evidence and value-based contracting frameworks to manage the budgetary implications of high-cost therapeutic innovations. Therefore, a strategic perspective that integrates R&D priorities, manufacturing capabilities, market access planning, and channel strategies is essential for advancing patient outcomes while maintaining commercial viability.

This executive summary synthesizes the critical drivers of change, examines policy and trade pressures affecting the industry, interprets segmentation and regional dynamics, and proposes actionable recommendations for leaders aiming to translate scientific promise into sustainable clinical and commercial impact. The analysis emphasizes the importance of multidisciplinary coordination, investment in evidence generation, and proactive supply chain management as core enablers for successful programs in the central nervous system therapeutic domain.

How precision modalities delivery innovations and regulatory adaptations are collectively transforming development commercialization and care delivery in CNS therapeutics

The landscape of central nervous system therapeutics is undergoing transformative shifts driven by converging technological, regulatory, and care delivery trends. Precision modalities such as gene therapy and monoclonal antibodies have matured from proof-of-concept into program phases that demand specialized manufacturing, targeted patient identification, and novel reimbursement constructs. Concurrently, advances in blood-brain barrier modulation and delivery platforms are expanding the range of feasible molecular interventions, enabling treatments that directly engage central nervous system targets with greater specificity and potentially fewer systemic effects.

Care delivery innovations are reshaping where and how therapies are administered. Hospitals continue to play a central role for acute and complex procedures, while clinics and home care settings are assuming greater responsibility for chronic management and post-acute therapy administration. This shift increases the importance of administration route design-injectable formulations require different logistical planning than oral or transdermal therapies-and places a premium on patient-friendly delivery systems and telehealth-enabled monitoring to maintain adherence and safety.

Meanwhile, regulatory frameworks are adapting to accommodate expedited pathways for high-impact therapies and to integrate novel endpoints and surrogate markers. Regulators are emphasizing robust safety monitoring and real-world evidence generation, which affects clinical development design and post-approval commitments. In parallel, stakeholders are accelerating collaboration across academic centers, contract development and manufacturing organizations, and specialty pharmacies to manage complexity and speed time to patient. These transformative shifts collectively favor organizations that can integrate scientific agility with operational rigor and stakeholder alignment across R&D, regulatory, manufacturing, and commercialization functions.

Assessment of evolving trade pressures and tariff-driven supply chain responses that are reshaping procurement manufacturing and access strategies across CNS therapeutics

The policy environment, including tariff actions, has tangible implications for ingredient sourcing, component supply, and the cost profile of therapeutics and devices used in central nervous system care. Tariff changes can amplify existing vulnerabilities in a sector that is reliant on specialized raw materials, single-source biologics components, and advanced manufacturing inputs. When duties increase on imported active pharmaceutical ingredients, viral vectors, or key manufacturing equipment, manufacturers face higher input costs that cascade through production schedules, inventory strategies, and pricing conversations with payers and providers.

Cumulative tariff impacts in 2025 are likely to accentuate strategic trade-offs for firms that have optimized global supply chains for cost-efficiency rather than resilience. In response, many organizations are evaluating nearshoring or regionalization strategies to reduce exposure to trade policy volatility, which can improve lead-time predictability but may require significant capital investment in local manufacturing capabilities. In addition, companies are reassessing supplier portfolios and qualifying alternative vendors to diversify sources for critical reagents and components. These adjustments can mitigate future tariff shocks but demand rigorous quality oversight and validation to preserve therapeutic integrity.

For hospitals and clinics, increased procurement costs driven by tariffs may translate into tighter budgetary pressure, prompting prioritization of therapies with clear value propositions and implementation of stricter formulary controls. Home care providers and distribution channels may be affected differently depending on their dependence on imported devices or specialty packaging. Overall, the cumulative effect of tariff changes is to elevate the importance of supply chain transparency, inventory optimization, and integrated cost mitigation strategies across procurement, manufacturing, and commercial functions.

Segment-driven strategic imperatives that align indication modality administration setting and distribution pathways to optimize development pathways and access outcomes

Segment-level nuances define opportunity windows and operational requirements across therapeutic development and commercialization activities. Based on Indication, studies cross Alzheimer's Disease, Attention Deficit Hyperactivity Disorder, Depression, Epilepsy, Multiple Sclerosis, Neuropathic Pain, Parkinson's Disease, and Stroke, each presenting unique patient identification challenges, endpoint selection complexities, and payer negotiations. Alzheimer's and Parkinson's programs emphasize disease modification and biomarker integration, ADHD and depression prioritize rapid symptomatic benefit and adherence, while epilepsy and stroke interventions often intersect with acute care delivery and rehabilitation pathways.

Based on Mechanism Of Action, the landscape includes Gene Therapy, Monoclonal Antibodies, Peptides, and Small Molecules, which impose distinct development and manufacturing footprints. Gene therapies demand expertise in vector design, cold-chain logistics, and long-term safety monitoring. Monoclonal antibodies require biologics manufacturing capacity and specialized distribution, whereas peptides and small molecules typically offer advantages in oral or transdermal delivery and generally lower manufacturing complexity, supporting broader access models.

Based on Route Of Administration, injectable, oral, and transdermal approaches create differentiated adoption and adherence profiles. Injectable modalities often align with clinic or hospital administration and can command premium reimbursement when paired with durable outcomes, whereas oral and transdermal therapies support outpatient and home care use, improving convenience but requiring strong adherence support programs. Based on End User, clinics, home care, and hospitals exhibit distinct procurement behaviors and clinical workflows, necessitating tailored training, support, and supply strategies for each setting. Based on Distribution Channel, hospital pharmacies, online pharmacies, and retail pharmacies represent varied access touchpoints that influence unit economics, patient experience, and channel-specific compliance and storage requirements.

Taken together, segmentation insights emphasize the imperative of aligning modality selection with end-user workflows, delivery route preferences, and distribution capabilities, while simultaneously addressing manufacturing constraints and evidence generation needs that differ markedly by indication and mechanism of action.

How regional regulatory ecosystems commercial infrastructures and supply chain strategies collectively influence development prioritization and global rollout planning

Regional dynamics shape development partnerships, regulatory strategies, and commercial entry sequencing in meaningful ways. The Americas region exhibits a strong ecosystem for clinical trial infrastructure, venture financing, and advanced biomanufacturing capacity, supporting the progression of high-complexity modalities and early commercialization of innovative therapies. Regulatory engagement and payer negotiations in this region require substantial evidence of clinical benefit and cost-effectiveness aligned with health system priorities.

Europe Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where centralized approval pathways coexist with national-level payer determinations. This variability necessitates flexible pricing and market access strategies, strong real-world evidence generation, and sometimes staggered launch approaches to accommodate divergent health technology assessment requirements and procurement practices.

Asia-Pacific includes both advanced markets with growing biotech capabilities and emerging markets with rapidly expanding access to specialty care. This region offers strategic opportunities for regional manufacturing partnerships, patient recruitment for diverse trial populations, and alternative pricing strategies to expand access. Across all regions, regionalization of supply chains, local regulatory intelligence, and culturally attuned patient engagement approaches are crucial to converting scientific advances into measurable health impacts and sustainable commercial returns.

Profiles of organizational differentiation driven by platform integration manufacturing strategies partnership models and evidence generation excellence

Leading organizations are differentiating through integrated platform capabilities, strategic alliances, and capability-building investments that address the unique demands of central nervous system therapeutics. Companies with vertically integrated biologics and gene therapy production resources are accelerating program timelines by reducing dependence on third-party capacity, while others prioritize partnerships with specialized contract developers and manufacturers to scale modal-specific production. In parallel, firms that invest in translational science, biomarker development, and companion diagnostics are improving patient selection and demonstrating clearer value propositions to payers and providers.

Commercial differentiation is also emerging through service-oriented strategies that support therapy delivery across varied care settings. Companies offering training programs for clinics and home care providers, bundled patient support services, and digital adherence tools are enhancing uptake and persistence, particularly for therapies requiring ongoing administration or complex monitoring. In the face of supply chain and tariff pressures, organizations that proactively diversify supplier networks, invest in quality oversight, and establish multi-regional manufacturing footprints are better positioned to maintain continuity of supply and negotiate with payers from a position of strength.

Finally, the most resilient players are executing disciplined evidence strategies that integrate randomized trial data with real-world outcomes and health economic modeling, enabling more compelling discussions with payers and health systems. This holistic approach-combining scientific innovation, manufacturing robustness, and tailored commercialization services-defines current leadership in the CNS therapeutics domain.

Practical prioritized actions for leaders to strengthen resilience adapt commercialization and accelerate patient access while preserving innovation momentum

Industry leaders should prioritize a set of pragmatic actions that balance innovation with operational resilience. First, invest in platform and delivery technologies that reduce dependency on single suppliers and enable flexible administration across hospitals clinics and home care settings. Second, accelerate investments in translational biomarkers and companion diagnostics to sharpen patient selection and improve the probability of meaningful clinical outcomes, thereby strengthening pricing and reimbursement discussions.

Third, restructure supply chain strategies to emphasize diversification and regional capacity, pairing nearshoring options with qualified contingency suppliers for critical reagents, viral vectors, and specialized components. Fourth, expand commercial services that facilitate adoption in non-traditional settings by developing training programs for clinicians, remote monitoring solutions, and patient support offerings that address adherence and safety in outpatient contexts. Fifth, adopt an integrated evidence strategy that blends rigorous clinical trial design with real-world evidence collection and economic modeling to support value-based contracting and formulary inclusion.

Finally, cultivate strategic partnerships across academia, contract manufacturing organizations, and specialty pharmacies to accelerate development and distribution while sharing risk. Implementing these prioritized actions will help organizations manage tariff volatility, operational complexity, and payer expectations while sustaining clinical innovation and improving patient access.

A multi-method research framework combining expert interviews literature synthesis segmentation mapping and scenario analysis to validate operationally relevant insights

The research approach combined qualitative and quantitative methods to ensure robustness and triangulation of findings. Primary inputs included structured interviews with clinical investigators health system leaders manufacturing and supply chain executives and commercial strategists to capture operational realities and emergent practice patterns. Secondary research encompassed peer-reviewed scientific literature, regulatory guidance documents, technical manufacturing publications, and policy analyses to inform understanding of modality-specific technical requirements and regulatory trajectories.

Analytical steps comprised segmentation mapping to reconcile indication, mechanism of action, route of administration, end-user, and distribution channel implications for development and commercialization strategies. Regional assessment applied regulatory and health system intelligence to contextualize market entry sequencing and supply chain design. Scenario analysis was used to evaluate the potential operational consequences of tariff adjustments and supply chain disruptions, informing recommendations for diversification and capacity investment.

Key limitations include variability in publicly available clinical outcome data across indications and the rapid evolution of regulatory guidance for novel modalities. To mitigate these constraints, findings were cross-validated with subject matter experts and supplemented by case examples of recent product launches and manufacturing scale-up programs to derive practical implications for decision-makers.

Concluding synthesis linking scientific advances regulatory and supply chain considerations to actionable strategic priorities for sustained clinical and commercial impact

In summary, central nervous system therapeutics occupy a dynamic space where scientific potential and operational complexity coexist. Progress in gene therapy, monoclonal antibodies, and advanced delivery platforms offers genuine potential to address unmet neurological needs, yet achieving clinical and commercial success requires an integrated strategy that spans translational science, manufacturing capability, supply chain resilience, and payer engagement. The interplay between administration routes and care settings underscores the need to design therapies and support services that fit clinic hospital and home care workflows to maximize uptake and adherence.

Policy and trade developments, including tariff changes, further emphasize the importance of proactive supply chain diversification, regional manufacturing investments, and flexible commercialization pathways. Regional differences in regulatory and reimbursement environments demand tailored approaches that align evidence generation, pricing strategies, and distribution planning with local stakeholder expectations. Companies that combine scientific differentiation with disciplined operational planning and targeted evidence strategies will be best positioned to convert innovation into sustained clinical impact and accessible care.

Ultimately, success in this sector depends on multidisciplinary coordination and the capacity to evolve organizational models in response to technological advances and external pressures, thereby delivering meaningful patient outcomes while preserving long-term commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of gene therapy modalities for treatment-resistant neurological disorders
  • 5.2. Integration of digital biomarkers into clinical trials to accelerate CNS drug development
  • 5.3. Expansion of monoclonal antibody therapies targeting amyloid and tau in Alzheimer's disease
  • 5.4. Growing focus on pharmacogenomics screening for personalized depression and anxiety management
  • 5.5. Increase in small molecule inhibitors addressing neuroinflammation pathways in Parkinson's disease
  • 5.6. Advancement of intrathecal and intranasal delivery platforms to overcome blood-brain barrier hurdles
  • 5.7. Strategic partnerships between biotech startups and big pharma for CNS pipeline diversification strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Central Nervous System Therapeutics Market, by Indication

  • 8.1. Alzheimer's Disease
  • 8.2. Attention Deficit Hyperactivity Disorder
  • 8.3. Depression
  • 8.4. Epilepsy
  • 8.5. Multiple Sclerosis
  • 8.6. Neuropathic Pain
  • 8.7. Parkinson's Disease
  • 8.8. Stroke

9. Central Nervous System Therapeutics Market, by Mechanism Of Action

  • 9.1. Gene Therapy
  • 9.2. Monoclonal Antibodies
  • 9.3. Peptides
  • 9.4. Small Molecules

10. Central Nervous System Therapeutics Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Transdermal

11. Central Nervous System Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Central Nervous System Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Central Nervous System Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Central Nervous System Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Central Nervous System Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Johnson & Johnson
    • 16.3.2. Roche Holding AG
    • 16.3.3. Novartis AG
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Biogen Inc.
    • 16.3.6. Merck & Co., Inc.
    • 16.3.7. AbbVie Inc.
    • 16.3.8. Eli Lilly and Company
    • 16.3.9. Teva Pharmaceutical Industries Ltd.
    • 16.3.10. Otsuka Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 258. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 259. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS CEN